Entrada Therapeutics Inc Total Liabilities
Entrada Therapeutics Inc total liabilities. Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has total liabilities worth $65.47 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Entrada Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Entrada Therapeutics Inc (2019–2025)
Total liabilities of Entrada Therapeutics Inc from 2019 to 2025. This chart illustrates how Entrada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Entrada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Entrada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spurcorp
JSE:SUR
|
South Africa | ZAC623.00 Million |
|
ProQR Therapeutics BV
NASDAQ:PRQR
|
USA | $54.05 Million |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
USA | $389.49 Million |
|
PT Arkora Hydro Tbk
JK:ARKO
|
Indonesia | Rp1.09 Trillion |
|
QuantaSing Group Limited American Depositary Shares
NASDAQ:QSG
|
USA | $335.14 Million |
|
Amcil Ltd
AU:AMH
|
Australia | AU$27.81 Million |
|
Dream Office Real Estate Investment Trust
TO:D-UN
|
Canada | CA$1.32 Billion |
|
GTM Holdings Corp
TW:1437
|
Taiwan | NT$5.53 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Entrada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Entrada Therapeutics Inc.
Liquidity & Leverage Metrics
Entrada Therapeutics Inc Total Liabilities Ratios Explained
Entrada Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entrada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entrada Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Entrada Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $71.25 Million | -27.04% |
| 2024-12-31 | $97.64 Million | -56.95% |
| 2023-12-31 | $226.83 Million | +474.23% |
| 2022-12-31 | $39.50 Million | +455.19% |
| 2021-12-31 | $7.12 Million | -91.63% |
| 2020-12-31 | $85.02 Million | +151.86% |
| 2019-12-31 | $33.76 Million | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potent… Read more